Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sai-Hong I, Ou"'
Autor:
Justin F. Gainor, MD, Shirish Gadgeel, M.B.B.S., Sai-Hong I. Ou, MD, PhD, Beow Yeap, ScD, Gregory A. Otterson, MD, Alice T. Shaw, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100045- (2020)
Introduction: RET rearrangements define a distinct molecular subset of NSCLC. The multikinase inhibitor ponatinib reveals potent activity in preclinical models of RET-rearranged NSCLC. Methods: In this single-arm, multicenter, phase II trial, we eval
Externí odkaz:
https://doaj.org/article/53f5be82f7374af8a8b945fa60ca91a8
Autor:
Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel, Rebecca S. Heist, Sai-Hong I. Ou, Jose M. Pacheco, Melissa L. Johnson, Joshua K. Sabari, Konstantinos Leventakos, Edwin Yau, Lyudmila Bazhenova, Marcelo V. Negrao, Nathan A. Pennell, Jun Zhang, Kenna Anderes, Hirak Der-Torossian, Thian Kheoh, Karen Velastegui, Xiaohong Yan, James G. Christensen, Richard C. Chao, Alexander I. Spira
Publikováno v:
New England Journal of Medicine. 387:120-131
Autor:
Lecia V. Sequist, Aaron N. Hata, Beni Wolf, Sai-Hong I. Ou, Corinne Clifford, Erica K. Evans, Alice T. Shaw, Rebecca S. Heist, A. John Iafrate, Mari Mino-Kenudson, Dora Dias-Santagata, Richard B. Lanman, Rebecca J. Nagy, Jessica J. Lin, Varuna Nangia, Amanda K. Riley, Satoshi Yoda, Wenjia Su, Subba R. Digumarthy, Mandeep K. Banwait, Nicolas Marcoux, Viola W. Zhu, Inga T. Lennes, Justin F. Gainor, Jochen K. Lennerz, Hideko Isozaki, Zofia Piotrowska
Supplementary Data and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc96358440634edc76f9afcf0d045e29
https://doi.org/10.1158/2159-8290.22534325.v1
https://doi.org/10.1158/2159-8290.22534325.v1
Autor:
Lecia V. Sequist, Aaron N. Hata, Beni Wolf, Sai-Hong I. Ou, Corinne Clifford, Erica K. Evans, Alice T. Shaw, Rebecca S. Heist, A. John Iafrate, Mari Mino-Kenudson, Dora Dias-Santagata, Richard B. Lanman, Rebecca J. Nagy, Jessica J. Lin, Varuna Nangia, Amanda K. Riley, Satoshi Yoda, Wenjia Su, Subba R. Digumarthy, Mandeep K. Banwait, Nicolas Marcoux, Viola W. Zhu, Inga T. Lennes, Justin F. Gainor, Jochen K. Lennerz, Hideko Isozaki, Zofia Piotrowska
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e051601bd88ba6af4840dc715298fa
https://doi.org/10.1158/2159-8290.22534322.v1
https://doi.org/10.1158/2159-8290.22534322.v1
Autor:
Sai-Hong I. Ou, Benjamin J. Solomon, Alice T. Shaw, Shirish M. Gadgeel, Benjamin Besse, Ross A. Soo, Antonello Abbattista, Francesca Toffalorio, Robin Wiltshire, Alessandra Bearz
Publikováno v:
Journal of Thoracic Oncology. 17:568-577
Lorlatinib, a potent, selective third-generation ALK tyrosine kinase inhibitor (TKI), exhibited overall and intracranial antitumor activity in patients with ALK-positive NSCLC.Retrospective analyses in the ongoing phase 2 trial (NCT01970865) investig
Autor:
Rona Yaeger, Jared Weiss, Meredith S. Pelster, Alexander I. Spira, Minal Barve, Sai-Hong I. Ou, Ticiana A. Leal, Tanios S. Bekaii-Saab, Cloud P. Paweletz, Grace A. Heavey, James G. Christensen, Karen Velastegui, Thian Kheoh, Hirak Der-Torossian, Samuel J. Klempner
Publikováno v:
N Engl J Med
BACKGROUND: Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies suggest that combining a KRAS G12C inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24015fad60764f1a91e6bb23f76efc78
https://europepmc.org/articles/PMC9908297/
https://europepmc.org/articles/PMC9908297/
Autor:
Petros Christopoulos, Thibaud Prawitz, Jin-Liern Hong, Huamao M. Lin, Luis Hernandez, Shu Jin, Min Tan, Irina Proskorovsky, Jianchang Lin, Pingkuan Zhang, Jyoti D. Patel, Sai-Hong I. Ou, Michael Thomas, Albrecht Stenzinger
Publikováno v:
Lung Cancer. 179:107191
Autor:
Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal
Publikováno v:
Lung Cancer. 179:107186
Autor:
Noura J, Choudhury, Jaime L, Schneider, Tejas, Patil, Viola W, Zhu, Debra A, Goldman, Soo-Ryum, Yang, Christina J, Falcon, Andrew, Do, Yunan, Nie, Andrew J, Plodkowski, Jamie E, Chaft, Subba R, Digumarthy, Natasha, Rekhtman, Maria E, Arcila, Alexia, Iasonos, Sai-Hong I, Ou, Jessica J, Lin, Alexander, Drilon
Publikováno v:
JTO Clinical and Research Reports
Introduction ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype hav
Autor:
J. Nicholas Bodor, Joanne Xiu, Vinicius Ernani, Supreet Kaur, Hirva Mamdani, Pavel Brodskiy, Sai-Hong I. Ou, Patrick C. Ma, Margie L. Clapper, W. Michael Korn, Joseph Treat
Publikováno v:
Cancer Research. 82:4119-4119
Background: While most EGFR-mutant NSCLC tumors are resistant to checkpoint inhibitors, a small subset has durable responses. Certain molecular subtypes of EGFR may be more responsive. There is a lack of clarity on the genomic and immune profiles of